What Impact Will Hepatitis C Drugs Have on Medical Costs? Ed Silverman
A new estimate suggests that, for private insurers, the impact of new hepatitis C treatments – including Sovaldi and any forthcoming medications – on medical costs will eventually decline, as will the impact on the growth in spending on overall health care. The notion is largely based on the current pricing for Sovaldi, which assumes forthcoming drugs would be similarly priced.
Two factors will be at work, according to PricewaterhouseCoopers Health Research Institute. Besides lowering the overall cost of treating hepatitis C sufferers, the market research firm maintains that the actual number of patients will gradually decline over the next decade as more patients are treated, including those whose physicians are waiting for better medications to become available.
Continue reading @ WSL
No comments:
Post a Comment